Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds William Blair Upgrades FibroGen to Outperform

William Blair Upgrades FibroGen to Outperform

William Blair analyst Andy Hsieh upgrades FibroGen (NASDAQ:FGEN) from Market Perform to Outperform.

byBenzinga Newsdesk

January 31, 2023

1 minute read

William Blair analyst Andy Hsieh upgrades FibroGen (NASDAQ:FGEN) from Market Perform to Outperform.

Barclays Maintains Overweight on SiTime, Lowers Price Target to $195

By Benzinga Newsdesk

August 4, 10:01 AM

Barclays analyst Blayne Curtis maintains SiTime (NASDAQ:SITM) with a Overweight and lowers the price target from $230 to $195.

SITM

Raymond James Initiates Coverage On Netstreit with Strong Buy Rating, Announces Price Target of $24

By Benzinga Newsdesk

September 14, 4:53 AM

Raymond James analyst RJ Milligan initiates coverage on Netstreit (NYSE:NTST) with a Strong Buy rating and announces Price Target of $24.

NTST

What’s Going On With Cannabis Stock SNDL?

By Erica Kollmann

April 4, 11:48 AM

SNDL shares are pulling back Thursday after the stock gained 22.6% Wednesday. The cannabis sector has rallied recently amid legalization in Germany and renewed optimism around the possible rescheduling of marijuana in the United States.

SNDL

Weekend Stock Spotlight: Apple, Tesla, Coinbase And Why Investors Don’t Expect A Midterm Election Market Rally

By Michael Cohen

October 2, 5:11 PM

Benzinga reviews this weekend's top stories covered by leading media outlets, here are the articles investors need to read.

AAPL

William Blair Upgrades FibroGen to Outperform

Related Posts

Barclays Maintains Overweight on SiTime, Lowers Price Target to $195

Raymond James Initiates Coverage On Netstreit with Strong Buy Rating, Announces Price Target of $24

What’s Going On With Cannabis Stock SNDL?

Weekend Stock Spotlight: Apple, Tesla, Coinbase And Why Investors Don’t Expect A Midterm Election Market Rally